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 Everything should be made as simple as possible but not simpler. 
Albert Einstein 
 
Hypertrophic cardiomyopathy is a common inherited disease that affects around 1 in 500 
people. In 50-60% of adolescents and adults with the condition, it is inherited as an 
autosomal dominant trait caused by mutations in cardiac sarcomere protein genes. A 
further 5% of patients have metabolic or storage disorders, neuromuscular disease, 
chromosome abnormalities and genetic syndromes such as cardio-facial-cutaneous 
disorders. While the disease is compatible with normal life expectancy, it is associated with 
premature death from ventricular arrhythmia, heart failure and stroke in a substantial 
minority of patients [1,2]. 
 
Approximately 25% of patients with HCM have a resting pressure gradient between the 
body and outflow tract of the left ventricle. This is nearly always caused by contact between 
the anterior mitral valve leaflet and the interventricular septum in systole. Some patients 
with no evidence of outflow obstruction at rest can develop it during physiologic and 
pharmacologic interventions which reduce left ventricular end-diastolic volume or increase 
left ventricular contractility. Current practice guidelines recommend echocardiography 
during exercise stress testing in non-obstructive patients with exertional symptoms as the 
demonstration of latent obstruction in this context has a profound effect on their 
subsequent management [1,2]. 
 
In this edition of the Journal, Maron and colleagues characterize a subset of patients that 
have HCM but no evidence of dynamic left ventricular outflow tract obstruction at rest or 
immediately following exercise [3]. Their major conclusion is that non-obstructive HCM 
carries a low risk of disease related adverse events including end-stage heart failure and 
cardiovascular death. Such a message is obviously good news for patients that fall into this 
category, but there is a danger that it may also be an oversimplification which–if interpreted 
uncritically in clinical practice–might result in a failure to monitor and treat patients whose 
disease is progressive and potentially life-threatening. 
 
A considerable body of evidence examining clinical outcomes in patients with HCM already 
exists. From these data we have learnt that patients with and with obstruction are 
vulnerable to disease related complications and careful examination of the data in the paper 
by Maron and colleagues suggests that their cohort is no different in this respect.  While the 
annual mortality in their study was less than 1%, the rate of disease related events–many of 
which were life-threatening or potentially disabling–was in fact quite high. Specifically, 34 
out of 249 non-obstructive patients (13.7%) died suddenly, had an appropriate ICD 
discharge or developed progressive heart failure, meaning that ≈2% of the cohort 
experienced a serious event each year. Add to this, the 19% that developed atrial fibrillation 
or stroke and the cumulative disease related morbidity and mortality is considerable. This 
finding is made all the more remarkable when one considers that the study cohort was 
biased towards individuals that most probably had a better outcome by excluding patients 
with severe heart failure symptoms at their initial evaluation.  
 
The low mortality in this study can be seen as a testament to the beneficial effect of 
targeted therapy–specifically, implantable cardioverter defibrillators, cardiac 
transplantation and stroke prophylaxis. However, the low annual death rate should not 
mask the fact that sudden cardiac death and progressive heart failure remain a significant 
problem in non-obstructive patients [4,5,6].  Prevention of sudden cardiac death is 
facilitated by the use of validated prediction tools and ever more sophisticated defibrillator 
technology [1,2]. In contrast, the treatment of progressive left ventricular dysfunction is 
largely empiric and is extrapolated (with no supporting evidence) from trials in patients with 
systolic heart failure caused by ischemic heart disease and dilated cardiomyopathy [1,2]. 
Nevertheless, as the study by Maron and colleagues corroborates, it is possible to identify a 
subset of patients at risk of end-stage heart failure by using a relatively simple clinical 
approach [1,2,4,5,6]. Patients at risk of heart failure require more frequent monitoring–
usually in a specialist setting–not only to treat symptoms, but also to detect the 
consequences of adverse cardiac remodeling including atrial arrhythmia and pulmonary 
hypertension, the latter a key factor determining the timing and suitability for cardiac 
transplantation. 
 
It is often implied that the attempt to understand hypertrophic cardiomyopathy is a fool’s 
errand because of its uniquely heterogeneous nature, but most published evidence suggests 
that adverse events are in fact predictable and often preventable. Modification of the 
underlying disease processes that result in ventricular failure is–at least for the moment–an 
aspiration, but research into this fascinating family of diseases is moving rapidly towards a 
focus on preventative and personalised interventions, built on an evermore sophisticated 
appreciation of their complex phenotypes.  
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